Paragon Research Corporation is at the forefront of leveraging artificial intelligence to revolutionize biomedical research and life science solutions. Our AI experts conduct in-depth research and utilize data and information from leading medical institutions to develop cutting-edge diagnostic and therapeutic models that push the boundaries of personalized medicine.

 Paragon has pioneered AI models for enhanced cancer detection and diagnosis in oncology. Using data from the prestigious Cancer Institute of the Cleveland Mayo Clinic, we developed an AI model capable of detecting 99.997% of breast cancer cases reported while significantly reducing instances of false positives. Our AI solutions have also delivered breakthrough capabilities for improved lung cancer identification from X-ray imagery and highly effective uterine cancer detection by fusing mass spectrometry data with tissue measurements.

Beyond oncology, Paragon’s biomedical AI research spans a range of disciplines. We have successfully created AI models that can detect the early onset of heart disease based solely on surface measurement data. Our work on Multiple Sclerosis (MS) has also yielded an AI model that identifies this autoimmune disorder by analyzing immune system response patterns.

Notably, our MS research formed the foundation for extending Paragon’s AI capabilities into the realm of Post-Traumatic Stress Disorder (PTSD). Our AI models can identify personalized treatment pathways by pinpointing molecular underpinnings and imitating medication side effects. Medical professionals from Meharry Medical School believe this AI-driven approach holds immense potential for application across other autoimmune disorders, pioneering a new era of precision medicine.

With expertise in AI/machine learning, multi-omics data integration, biomedical imaging, and close collaboration with esteemed medical research partners, Paragon is unlocking the power of AI to transform disease diagnosis and treatment and accelerate biomedical breakthroughs.